Agilent Technologies Names IMAXIO as Certified Provider of Target Enrichment Services for Next-Gen Sequencing
SANTA CLARA, Calif., July 3, 2012
Agilent Technologies Inc. (NYSE: A) today announced that IMAXIO has achieved Certified Service Provider status for the Agilent SureSelect Target Enrichment System for next-generation sequencing. IMAXIO has been a certified provider of Agilent microarray services for several years, and the company increased its service offerings in the beginning of 2012 by successfully passing Agilent's SureSelect service provider certification.
IMAXIO, an integrated biotech company that focuses on genomics and vaccine research, provides a wide range of integrated genomics services, including microarray-based studies (comparative genomic hybridization and transcriptomics studies) and next-generation approaches for both DNA and RNA sequencing. IMAXIO recently improved its throughput capabilities with the acquisition of the Agilent automated workstation for NGS library and microarray sample preparation.
"This new target enrichment certification is an important step in order to strengthen our partnership with Agilent and to adapt to increased demand for integrated genomics," said Dr. Véronique Vidal, head of IMAXIO's Genomics Division.
"SureSelect is the leader in NGS target enrichment, with over 250 publications," said Kathleen Shelton, senior director of Genomics Marketing at Agilent. "We look forward to a productive and rewarding partnership with IMAXIO."
To achieve Certified Service Provider status, IMAXIO participated in comprehensive on-site training and then passed a rigorous set of requirements to demonstrate expertise and skill.
SureSelect is compatible with major NGS platforms such as Illumina, SOLiD and 454. Users of Agilent's eArray design tool can improve the efficiency of their research by easily designing custom products to target any genomic region of interest. SureSelect also allows customization of catalog kits with the addition of custom content.
IMAXIO is a biopharmaceutical company specialized in the areas of genomics and vaccines. The genomic division is involved in programs for the development of companion and diagnostic tests in human health. IMAXIO is developing, both individually and with its partners, recombinant vaccines for applications in both human and animal health. In France, IMAXIO already markets Spirolept, a human vaccine against leptospirosis. For more information, go to www.genomics-imaxio.com.
About Agilent in Genomics
Agilent Technologies Inc. is a global leader in target enrichment for next-generation sequencing and genomic microarrays. The Agilent SureSelect and HaloPlex target enrichment systems enable researchers to easily choose which segments of a genome to sequence, avoiding the time and expense needed to sequence the entire genome. HaloPlex and its same day sample-to-sequencer workflow is well suited for next-gen desktop sequencers, whereas SureSelect's ability to accurately capture whole exomes and whole methylomes in a single reaction pairs well with high-throughput next-gen sequencing systems. These are just two products arising from Agilent's expertise in synthesizing custom complex mixtures of long oligonucleotide gained in microarray manufacturing. Additional product lines built on this core technology include microarrays for genome-wide measurement of gene expression and for comparative genomics hybridization, as well as SureFISH, a highly specific and sensitive oligonucleotide flourescent in situ hybridization product line. In addition to oligonucleotide-based products, Agilent offers a microfluidic bioanlyzer to measure sample quality, a target enrichment tool to speed next-generation sequencing, and a full set of reagents, hardware, methods and bioinformatics software for genomic experiments.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,000 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available at www.agilent.com.
# # #
+1 408 553 2005